OPRX
Get informed when a big investor buys or sells
+ FollowOvervalued by 32.9% based on the discounted cash flow analysis.
| Market cap | $155.37 Million |
|---|---|
| Enterprise Value | $151.47 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.28 |
| Beta | 1.09 |
| Outstanding Shares | 18,785,596 |
| P/E Ratio | 33.99 |
|---|---|
| PEG | -23.3 |
| Price to Sales | 1.83 |
| Price to Book Ratio | 1.53 |
| Enterprise Value to Revenue | 1.54 |
| Enterprise Value to EBIT | 136.58 |
| Enterprise Value to Net Income | 32 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.15 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 114.10% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 59.67% |
|---|---|
| Total Invested | $119,730▼ 99.81% |
| Investors Holding | 6▼ 111.00% |
No data
OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary ne...